Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs)

9:30 am - Thursday 29th October 2026

  • Development of highly potent (<500 pM) AURKB PROTACs from legacy target binders
  • Modification of PROTACs to allow for conjugation to DACs
  • Assessment of what PROTAC physicochemical properties make for good DAC payloads

Speakers:

Associate Director, Medicinal Chemistry
AstraZeneca